Journal
SEMINARS IN IMMUNOLOGY
Volume 20, Issue 5, Pages 286-295Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2008.09.006
Keywords
Cancer; Immunotherapy; Antigen; Tolerance; Clinical trial
Categories
Funding
- Queensland Cancer Fund
- National Health and Medical Research Council of Australia
Ask authors/readers for more resources
Progress in tumor immunology has not been translated to effective immunotherapies for cancer. Most of the current effort in basic and clinical research concentrates on generating effective immune responses against model or well characterized antigens, yet vaccines targeting defined antigens have been less clinically successful than those based on whole tumor cells or their extracts. This review considers characteristics of proteins that determine how effectively they might serve as targets of immune control, and how different sources of antigens have fared in clinical trials. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available